Correlation between heart type fatty acid binding protein and mild & severe COVID-19

doi:10.3969/j.issn.1004-583X.2022.12.007

Abstract

Abstract:

Objective To analyze the clinical characteristics of patients with mild & severe corona virus disease 2019 (COVID-19) and explore the correlation between herart fatty acid binding protein(H-FABP)and mild & severe COVID-19. Methods Totally 40 patients with negative expression of high-sensitivity troponin T (hs-cTnT) admitted to the Chongqing University Three Gorges Hospital before June 2022 were retrospectively analyzed. According to the diagnostic criteria of “Diagnosis and Treatment Protocol for COVID-19 (Trial Version 8)”, the patients were enrolled into the mild and severe groups. The expression levels of H-FABP in peripheral blood were compared between the two groups. Results Eligible 40 COVID-19 patients representing 20 cases in the mild group and 20 cases in the severe group were included. Compared with the mild group, the patients in the severe group were older ([41.9±10.5] vs [58.2±16.3]) years, and the proportion of patients with diabetes was higher (all P<0.05). H-FABP level in the severe group was significantly higher than that in the mild group ([3.97±1.80] vs [6.88±3.90] μg/L; [P<0.05], respectively). Conclusion In COVID-19 patients with negative hs-cTnT expression, serum H-FABP expression level is associated with the severity of COVID-19 disease. H-FABP may serve as a more sensitive and independent myocardial injury factor to contribute to the disease typing of COVID-19.

Key words: corona virus disease 2019, herart fatty acid binding protein, the severity of COVID-19 disease

CLC Number:

R563.1

Guo Wenxiu, Wang Hailong, Wang Doudou. Correlation between heart type fatty acid binding protein and mild & severe COVID-19[J]. Clinical Focus, 2022, 37(12): 1104-1107.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.12.007

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I12/1104

Figures/Tables 2

References 17

[1]	Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global emergency:A review of the 2019 novel coronavirus (COVID-19)[J]. Int J Surg, 2020, 76:71-76. doi: S1743-9191(20)30197-7 pmid: 32112977
[2]	Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2021, 19(3):141-154. doi: 10.1038/s41579-020-00459-7 pmid: 33024307
[3]	中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组. 新型冠状病毒肺炎流行病学特征分析[J]. 中华流行病学杂志, 2020, 41(2):145-151.
[4]	Kakoti A, Goswami P. Heart type fatty acid binding protein: structure,function and biosensing applications for early detection of myocardial infarction[J]. Biosens Bioelectron, 2013, 43:400-411. doi: 10.1016/j.bios.2012.12.057 URL
[5]	中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版修订版)[J]. 中华临床感染病杂志, 2021, 14(2):81-88.
[6]	Jutzeler CR, Bourguignon L, Weis CV, et al. Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19:A systematic review and meta-analysis[J]. Travel Med Infect Dis, 2020, 37:101825. doi: 10.1016/j.tmaid.2020.101825 URL
[7]	耿梦杰, 任翔, 余建兴, 等. 不同年龄组新型冠状病毒肺炎患者临床特征分析[J]. 疾病监测, 2021, 36(6):573-580.
[8]	Mori H, Obinata H, Murakami W, et al. Comparison of COVID-19 disease between young and elderly patients: Hidden viral shedding of COVID-19[J]. J Infect Chemother, 2021, 27(1):70-75. doi: 10.1016/j.jiac.2020.09.003 pmid: 32950393
[9]	Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis[J]. Eur Respir J, 2020, 55(5):2000547. doi: 10.1183/13993003.00547-2020 URL
[10]	Jiménez-Ruiz CA, López-Padilla D, Alonso-Arroyo A, et al. COVID-19 and smoking: A systematic review and meta-analysis of the evidence[J]. Arch Bronconeumol, 2021, 57:21-34.
[11]	曾睿, 贺晓洁, 海冰. 新型冠状病毒肺炎与吸烟的相关性研究进展[J]. 现代预防医学, 2021, 48(19):3616-3621.
[12]	Goel H, Melot J, Krinock MD, et al. Heart-type fatty acid-binding protein: An overlooked cardiac biomarker[J]. Ann Med, 2020, 52(8):444-461. doi: 10.1080/07853890.2020.1800075 pmid: 32697102
[13]	Pesce M, Agostoni P, Bøtker HE, et al. COVID-19-related cardiac complications from clinical evidences to basic mechanisms: Opinion paper of the ESC Working Group on Cellular Biology of the Heart[J]. Cardiovasc Res, 2021, 117(10):2148-2160. doi: 10.1093/cvr/cvab201 URL
[14]	Lindner D, Fitzek A, Bräuninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases[J]. JAMA Cardiol, 2020, 5(11):1281-1285. doi: 10.1001/jamacardio.2020.3551 URL
[15]	Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management[J]. Heart Rhythm, 2020, 17(9):1463-1471. doi: S1547-5271(20)30422-7 pmid: 32387246
[16]	洪仲思, 郑新春, 杨小月, 等. 对比分析18例重症/危重症新型冠状病毒肺炎心肌损伤患者临床特征[J]. 中国动脉硬化杂志, 2020, 28(4):290-295.
[17]	刘自强, 缪锦峰, 邹琼, 等. 新型冠状病毒肺炎患者发生复合终点事件危险因素的meta分析[J]. 临床荟萃, 2020, 35(9):773-782.

项目	轻症 (n=20)	重症 (n=20)	t/ χ²值	P值
年龄(岁)	41.9±10.5	58.2±16.3	-3.769	0.001
性别[例(%)]
男女	14(70.0) 6(30.0)	10(50.0) 10(50.0)	1.667	0.197
吸烟[例(%)]	2(10.0)	1(5.0)	0	1.000
临床病史[例(%)]
糖尿病	0(0)	7(17.5)	6.234	0.013
高血压病	2(10.0)	1(5.0)	0	1.000
心血管疾病	0(0)	2(10.0)	0.526	0.468
慢性阻塞性肺疾病 [例(%)]	1(5.0)	2(10.0)	0	1.000
慢性肝病	1(5.0)	1(5.0)	0	1.000
慢性肾病	0(0)	0(0)	-	-
恶性肿瘤	0(0)	0(0)	-	-

项目	轻症 (n=20)	重症 (n=20)	t/ χ²值	P值
年龄(岁)	41.9±10.5	58.2±16.3	-3.769	0.001
性别[例(%)]
男女	14(70.0) 6(30.0)	10(50.0) 10(50.0)	1.667	0.197
吸烟[例(%)]	2(10.0)	1(5.0)	0	1.000
临床病史[例(%)]
糖尿病	0(0)	7(17.5)	6.234	0.013
高血压病	2(10.0)	1(5.0)	0	1.000
心血管疾病	0(0)	2(10.0)	0.526	0.468
慢性阻塞性肺疾病 [例(%)]	1(5.0)	2(10.0)	0	1.000
慢性肝病	1(5.0)	1(5.0)	0	1.000
慢性肾病	0(0)	0(0)	-	-
恶性肿瘤	0(0)	0(0)	-	-

组别	例数	H-FABP
轻型组	20	3.97±1.80
重型组	20	6.88±3.90
t值		-3.037
P值		0.005

组别	例数	H-FABP
轻型组	20	3.97±1.80
重型组	20	6.88±3.90
t值		-3.037
P值		0.005